| 8th Sep 2026 2:00 pm |
RNS |
Imfinzi+Imdelltra improved OS in small cell lung |
| 7th Sep 2026 7:00 am |
RNS |
Etcamah approved in the US for HR+ breast cancer |
| 1st Sep 2026 3:05 pm |
RNS |
Admission of Further Securities to Trading |
| 1st Sep 2026 3:00 pm |
RNS |
Total Voting Rights |
| 1st Sep 2026 11:00 am |
RNS |
Admission to Trading - €2.55 billion bond offering |
| 1st Sep 2026 7:30 am |
RNS |
Enhertu approved in EU for 1L HER2-positive mBC |
| 1st Sep 2026 7:10 am |
RNS |
Directorate change |
| 1st Sep 2026 7:05 am |
RNS |
AstraZeneca completes agreement for Zegfrovy |
| 1st Sep 2026 7:00 am |
RNS |
Tagrisso + Orpathys improved PFS in 1L EGFRm lung |
| 27th Aug 2026 7:00 am |
RNS |
Tezspire CROSSING trial met primary endpoints |
| 25th Aug 2026 7:00 am |
RNS |
AstraZeneca prices a €2.55 billion bond offering |
| 19th Aug 2026 11:00 am |
RNS |
Director/PDMR Shareholding |
| 17th Aug 2026 7:30 am |
RNS |
Enhertu improved PFS in 1L HER2m lung cancer |
| 17th Aug 2026 7:05 am |
RNS |
Update on eVOLVE-Lung02 Phase III trial |
| 17th Aug 2026 7:00 am |
RNS |
Tagrisso+Orpathys improved PFS & OS in EGFRm lung |
| 3rd Aug 2026 3:05 pm |
RNS |
Admission of Further Securities to Trading |
| 3rd Aug 2026 3:00 pm |
RNS |
Total Voting Rights |
| 31st Jul 2026 7:30 am |
RNS |
Datroway approved in EU for TNBC |
| 27th Jul 2026 7:10 am |
RNS |
Update on Ultomiris Phase III trial in HSCT-TMA |
| 27th Jul 2026 7:05 am |
RNS |
Sone-Ve improved survival in gastric cancers |
| 27th Jul 2026 7:00 am |
RNS |
Half-year Financial Report |
| 23rd Jul 2026 7:00 am |
RNS |
Etcamah approved in the EU for ER+ breast cancer |
| 14th Jul 2026 7:00 am |
RNS |
AstraZeneca licenses novel EGFR inhibitor |
| 9th Jul 2026 7:00 am |
RNS |
Update on CARDIO-TTRansform Phase III trial |
| 1st Jul 2026 3:05 pm |
RNS |
Admission of Further Securities to Trading |
| 1st Jul 2026 3:00 pm |
RNS |
Total Voting Rights |
| 29th Jun 2026 7:30 am |
RNS |
Enhertu approved in EU for HER2+ solid tumours |
| 29th Jun 2026 7:00 am |
RNS |
Datroway recommended for approval in EU for TNBC |
| 15th Jun 2026 7:00 am |
RNS |
Truqap approved in US for prostate cancer |
| 1st Jun 2026 3:05 pm |
RNS |
Admission of Further Securities to Trading |
| 1st Jun 2026 3:00 pm |
RNS |
Total Voting Rights |
| 29th May 2026 7:00 am |
RNS |
Imfinzi approved in US for early bladder cancer |
| 27th May 2026 7:00 am |
RNS |
US FDA decision date on camizestrant extended |
| 26th May 2026 7:00 am |
RNS |
Enhertu recommended in EU for HER2+ solid tumours |
| 26th May 2026 7:00 am |
RNS |
Camizestrant recommended for breast cancer in EU |
| 26th May 2026 7:00 am |
RNS |
Datroway approved in US for 1L triple-negative BC |
| 18th May 2026 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 18th May 2026 7:05 am |
RNS |
Enhertu approved in two HER2+ early BC settings |
| 18th May 2026 7:00 am |
RNS |
Baxfendy approved in the US for hypertension |
| 14th May 2026 7:00 am |
RNS |
Imfinzi + EV improves EFS & OS in bladder cancer |
